Abstract Body

Background:

We have previously reported that circulating endothelial cell derived extracellular microvesicles (EMVs) are elevated in adults living with HIV (ALWH) receiving antiretroviral therapy (ART) contributing to endothelial vasodilator dysfunction by negatively affecting endothelial nitric oxide synthase (eNOS) and, in turn, impairing NO production. However, whether elevations in circulating EMVs and their pathologic effects on endothelial NO production was a direct effect of HIV-1 or a consequence of ART is unknown. The experimental aims of this study were to determine: 1) whether circulating EMVs are elevated in treatment-naïve ALWH and associated with HIV-1-related endothelial vasodilator dysfunction; and 2) the effects of EMVs isolated from treatment-naïve ALWH on endothelial cell NO production, in vitro.

Methods:

Twenty-four sedentary, adults were studied: 12 healthy (10M/2F; age 35±2 yr) and 12 treatment naïve ALWH (10M/2F; 35±2 yr; viral load: 7342 copies/mL). All subjects were non-obese, normotensive, normolipidemic and free of overt cardiometabolic disease. Circulating EMV (CD144-PE) number was determined by flow cytometry. Forearm blood flow (FBF: via plethysmography) was assessed by intra-arterial infusion of acetylcholine and sodium nitroprusside. Human coronary artery endothelial cells were cultured and treated with EMVs (CD144-PE) isolated from the healthy and treatment naïve ALWH.

Results:

Circulating EMVs were ~75% higher (P<0.05) in the treatment naïve ALWH (234±20 EMV/μL) vs healthy (135±13 EMV/μL) adults. FBF responses to acetylcholine were significantly lower (~20%) in the treatment naïve ALWH adults (from 5.6±0.3 to 12.6±1.1 mL/100 mL tissue/min vs 4.9±0.2 to 15.8±1.1 mL/100 mL tissue/min). There were no significant differences between the groups in FBF response to sodium nitroprusside. EMVs were strongly and inversely associated with the vasodilator response to acetylcholine (r=-0.49; P=0.01). Moreover, expression of phosphorylated eNOS (78.5±6.1 vs 102.9±7.9 AU) and NO production (6.0±0.4 vs 7.3±0.4 μmol/L) was significantly lower in cells treated with EMVs from treatment naïve ALWH vs healthy adults.

Conclusions:

HIV-1 is associated with elevated circulating EMVs. Moreover, circulating EMVs are not only a systemic biomarker, but appear to be a mechanistic factor underlying endothelial dysfunction with HIV-1. Circulating EMVs represent a novel causative factor underlying vascular abnormalities and the increased CVD risk associated with HIV-1.